First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects

ALPN‐101 (ICOSL vIgD‐Fc) is an Fc fusion protein of a human inducible T cell costimulatory ligand (ICOSL) variant immunoglobulin domain (vIgD) designed to inhibit the cluster of differentiation 28 (CD28) and inducible T cell costimulator (ICOS) pathways simultaneously. A first‐in‐human study evaluat...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jing, Lickliter, Jason D., Hillson, Jan L., Means, Gary D., Sanderson, Russell J., Carley, Kay, Tercero, Almudena, Manjarrez, Kristi L., Wiley, Jennifer R., Peng, Stanford L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301585/
https://www.ncbi.nlm.nih.gov/pubmed/33503289
http://dx.doi.org/10.1111/cts.12983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8301585/
https://www.ncbi.nlm.nih.gov/pubmed/33503289
http://dx.doi.org/10.1111/cts.12983

Ejemplares similares